This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Anti-CD321 antibody immunotherapy protects liver against ischemia and reperfusion-induced injury
Scientific Reports Open Access 18 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Nakamura, K. et al. Antibiotic pretreatment alleviates liver transplant damage in mice and humans. J. Clin. Invest. 129, 3420–3434 (2019)
Panel, M. et al. Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia–reperfusion injury. Gastroenterology https://doi.org/10.1053/j.gastro.2019.07.026 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dickson, I. Improving hepatic ischaemia–reperfusion injury outcomes. Nat Rev Gastroenterol Hepatol 16, 583 (2019). https://doi.org/10.1038/s41575-019-0194-y
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41575-019-0194-y
This article is cited by
-
Loureirin B improves H/R-induced hepatic ischemia–reperfusion injury by downregulating ALOX5 to regulate mitochondrial homeostasis
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Anti-CD321 antibody immunotherapy protects liver against ischemia and reperfusion-induced injury
Scientific Reports (2021)